News

In an era of personalized medicine in oncology, monoclonal antibodies, bispecific T-cell engagers, and CAR T-cell therapies are revolutionizing patient outcomes in multiple myeloma.

The FDA granted a breakthrough therapy designation to abatacept for the prevention of moderate to severe acute graft-versus-host disease in hematopoietic stem cell transplants from unrelated donors.

Miguel-Angel Perales, MD, discusses the evolving role of CAR T-cell therapy in diffuse large B-cell lymphoma and follicular lymphoma.

Research on chimeric antigen receptor T-cell therapy to be presented at the ASH Annual Meeting & Exposition is set to address drawbacks associated with treatment.

Robert A. Brodsky, MD discussed the study of a first-of-kind multi-antigen targeted off-the-shelf chimeric antigen receptor- natural killer cell therapy with engineered persistence that will be presented at the ASH Annual Meeting & Exposition.

Nina Shah, MD, discusses how CAR T-cell therapy, bispecific T-cell engagers, and antibody-drug conjugates are being used to treat patients with multiple myeloma.

Mavacamten is a first-in-class small-molecule therapy that reduces the contractility of cardiac muscles by binding with myosin, a protein involved in muscle contraction that is often affected by a gene mutation in hypertrophic cardiomyopathy.

New findings from ESCaPE-MD show CD34+ cell therapy significantly benefitted patients with coronary microvascular dysfunction over 6 months.

The FDA has granted an accelerated approval to zanubrutinib capsules for the treatment of adult patients with mantle cell lymphoma who have received ≥1 prior therapy.

Luca Biavati, MD, from Johns Hopkins Medicine, discussed bone marrow T-cells and bone marrow infiltrating lymphocytes as a source for adoptive cell therapy at the 34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019).

This is the third safety incident in the IGNITE DMD clinical trial that has resulted in a clinical hold since its inception in 2017.

Joseph A. Sparano, MD, discusses using gene expression profiles as a means to guide therapy in breast cancer.

The evidence shows that chimeric antigen receptor (CAR) T-cell therapies are effective, but the price tags on these treatments are high and have raised concerns about how many patients will get treated. During a discussion at The American Journal of Managed Care®’s Patient-Centered Oncology Care® meeting, held Friday in Philadelphia, panelists outlined the efficacy of the 2 FDA-approved therapies, Medicare reimbursement for CAR T-cell therapies, and the pace of innovation in healthcare.

Ixazomib significantly improved progression-free survival as a first-line maintenance therapy compared with placebo in adult patients with multiple myeloma who have not undergone stem cell transplantation, meeting the primary endpoint of the phase III TOURMALINE-MM4 study.

The University of Texas MD Anderson Cancer Center and Takeda Pharmaceutical Company Limited have entered an exclusive license agreement and research agreement to develop and market chimeric antigen receptor-directed natural killer-cell therapies.

Anti-BCMA directed treatments, including CAR T-cell therapy, bispecific antibodies, and antibody-drug conjugates, have the potential to revolutionize the multiple myeloma treatment paradigm. At the 37 Annual CFS®, Sham Mailankody, MBBS, discussed the emerging BCMA-directed therapies that have shown the greatest potential.

The FDA has granted a Regenerative Medicine Advanced Therapy designation to the investigational anti-BCMA CAR T-cell therapy CT053 for the treatment of patients with relapsed/refractory multiple myeloma.

A lawsuit filed by a former executive of Juul claims they knowingly sold 1 million contaminated pods; Novartis trial for its Zolgensma gene therapy stopped amid safety concerns; charts show worsening air quality in Louisiana.

William G. Wierda, MD, PhD, discusses the evolving treatment paradigm in chronic lymphocytic leukemia and ongoing trials looking at novel approaches.

Results of a phase 1 study examining a potential gene therapy for x-linked retinitis pigmentosa showcased improvements in microperimetry and a favorable safety profile.

While antiretroviral therapy (ART) can suppress HIV infection, ART cannot completely eradicate HIV, which remains in a latent reservoir in CD4-positive T cells during treatment; discontinuation of ART leads to rapid rebound of the virus. This reservoir forms even when ART is initiated early on in the infection, and while the most widely accepted model of how the reservoir forms involves infection of a CD4-positive T cell as it transitions to a resting state, the dynamics and timing of the reservoir’s formation have been largely unknown.

The rAAV2/2-ND4 gene therapy GS010 elicited continuous bilateral improvements in BCVA from week 48 to week 96 for patients with Leber hereditary optic neuropathy.

How much do you know about the role of CAR T cells in multiple myeloma? Here's your chance to find out.

According to Jeffrey Heier, MD, RGX-314 administered by subretinal injection was well tolerated. In addition, it was associated with dose-dependent increase in ocular protein expression and evidence of clinical benefit.

Treatment with subretinal transplantation of allogeneic human retinal progenitor cells showed promising early signs of efficacy as a treatment for individuals with retinitis pigmentosa.